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INTRODUCTION
Treatment of end-stage renal disease patients with dialysis and its modalities is, possibly, one of the greatest achievements of medicine in general (1) . Organ transplantation is a huge step ahead in treatment of these patients (2). It not only provides better life quality, but lenghtens life expectancy in comparison to treatment by methods of dialysis (3, 4, 5, 6, 7) . During mid 70's transplantations have been done in Sarajevo, Bosnia and Herzegovina, which in that period was almost spectacular given the circumstances that it has gone not more that 20 years since the first transplantation in the world. Owing thanks to Professors Bošković and Macanović, Sarajevo, alongside Rijeka, was the leading transplantation center in former Yugoslavia (8, 9) . Nowadays transplantations are done not only in Sarajevo but in Tuzla and Banja Luka as well. It is a fact that dialysis significantly increases life expectancy and eliminates many medical complaints that untreated patients with end-stage renal disease endure. However, that type of treatment is associated with many complications because dialysis does not fully compensate for normal renal function. Patients commonly suffer from anemia and bone diseases, with their cardiovascular system being at risk as well. By introducing transplantation as treatment possibility many of these problems are surpassed because transplanted kidney regulates and modifies occurrence of complaints that endstage renal disease patients might occur. It could be said that treatment by transplantation is by far the best treatment for end-stage renal disease. And although living-donor transplantation is the most widespread, being even the only modality of transplantation in some countries, transplantation trends should focus toward deceased-donor transplantation (10) . Renal transplantation as highly sophisticated renal replacement therapy was started in UCC Tuzla in September of 1999.
PATIENTS AND METHODS
Over period of 13 years (1999 until January 2011) total of 100 renal transplantations have been performed in UCC Tuzla, making it 7.69 transplantations annually. Chronic dialysis patients from different dialysis centers in Bosnia and Herzegovina underwent transplantation, 68% of them being males and 32% females. were mostly performed (88), followed by deceased donor (11) and one spousal kidney transplantation (1) ( Figure  3 ). Most commonly donors were mothers (31), fathers (26), sisters (13), brothers (12) , other family members (7), and cadaver (11) (Figure  4) . In the beginning patients were treated with cyclosporine, azathioprine and corticosteroids, with polyclonal antibodies (antithymocite globulin) being used as induction therapy. The usage of mycophenolate-mofetil (CellCept) started in 2002 followed by introduction of basiliximab (Simulect) later that year. Tacrolimus (Prograf) was first introduced in therapy in June 2008. First transplantation under desensitization protocol was carried out in December 2009, and it included phlasmapheresis, immunoglobulins and rituximab. In year 2011 first planned pregnancy in a woman with transplanted kidney was carried out.
RESULTS
Results have been presented by Kaplan-Meier estimator and curve. One year renal graft survival rate in our patients is 94%, and 5-year renal graft survival rate is 75%. Average time until loss of graft function was 93 months (%95 confidence interval from 82 to 104 months) in all patients, and 49 months (%95 confidence interval from 36 to 62 months) only in group of patients with loss of graft function ( Figure 5) . Oneyear patient survival rate was 96%, 5-year patient survival rate being 84%. Average time until lethal outcome was 111 months (%95 confidence interval from 101 to 121 months), and in patients with lethal outcome death occurred after 44 months in average (%95 confidence interval from 27 to 61 months) ( Figure 6 ).
DISCUSSION
The total and mean annual number of transplantations in our center is relatively low, yet at this moment we are still leaders in our country by number and Our results are better than some countries of our region provide, although some other countries are still ahead of us. The rates of performed transplantations are insufficient to solve the problem of growing numbers of end-stage renal disease patients, but it makes quite the ground for experience building and professional improvement. Results are among percentile ranges of efficacy based on patient and graft survival. International guidelines suggest that 1-year survival rate for renal graft should be at least 85% and not lower than 70% 5-years after transplantation. Our results are 95% for 1-year renal graft survival and 75% for 5-year renal graft survival. Guidelines for patient survival rates are 90% after 1-year and 85% 5-year following transplantations, with our results indicating 1-year patient survival rate of 96%, 5-year survival rate of 84%. Optimal graft function is obtained by sensitive maintenance of balance among underdosed drugs and graft rejection at one end, and drug overdose and their induced toxicity at another end (12).
CONCLUSION
Number of performed transplantations would have been greater if our country had health care system that would regulate issues of promotion and realization of deceased donor transplantation. Current laws are not perfect, but they make ground for eventual alterations. Continuous education is cardinal factor in improvement of healthcare in transplantation. Probably the best way to increase the number of performed transplantations would be joining an European association such as Eurotransplant, which is basically our bottom line goal.
